Logo
Revitrane Premium SubQ 1 x 1ml

Revitrane Premium SubQ 1 x 1ml

Revitrane

Medical aesthetics
  • CE Marked hyaluronic acid dermal filler (Revitrane Premium range, including SubQ variant).
  • Manufactured under ISO 13485 Compliant quality management system for medical devices.
  • GMP Compliant production facilities operated by BR PHARM Co., Ltd.
  • Use of high Quality, pharmaceutical Grade, non Animal hyaluronic acid raw materials.
  • Minimised BDDE cross Linking rate and advanced BDDE residual washing technology to reduce residual cross Linker.
  • Low endotoxin levels to decrease risk of inflammatory reactions.
  • Distributed via regulated aesthetic pharmacies and wholesalers that operate within applicable EU/UK medical device and supply Chain standards.
Hyaluronic acid dermal filler

Description

Revitrane Premium SubQ is a high-viscosity, cross-linked hyaluronic acid dermal filler and the thickest, most durable product in the Revitrane range. Designed for deep facial augmentation and the treatment of very deep wrinkles, it restores lost volume, smooths pronounced folds and enhances facial contours with strong structural support and sharp definition. Containing 20 mg/mL of cross-linked hyaluronic acid in a dense, cohesive gel, Premium SubQ is ideal for jawline contouring, chin augmentation and cheek sculpting, providing long-lasting, natural-looking results with excellent projection and facial symmetry.

Bnefits

  • Thickest and most durable filler in the Revitrane portfolio, ideal for deep to very deep wrinkles and structural augmentation.
  • Restores volume in deep facial lines and folds for a more youthful, lifted appearance.
  • Enhances and sharpens facial contours, particularly in the jawline, chin and cheeks.
  • Smooths deep wrinkles and pronounced nasolabial folds while maintaining natural facial expression.
  • High viscoelasticity and cohesiveness provide strong lifting power and long-lasting shape retention.
  • Large particle size and dense gel reduce risk of migration and maintain definition at the injection site.
  • Soft, integrated gel with low endotoxin levels designed for safe injection and predictable outcomes.
  • Helps hydrate and plump the skin in treated areas, improving overall skin quality and firmness.
  • Results typically last up to around 10 months, depending on area, technique and patient factors.
  • Manufactured with minimised BDDE cross-linking and advanced BDDE residual cleaning processes for an improved safety profile.

Indications

  • Deep wrinkles and folds requiring strong volumisation and support.
  • Pronounced nasolabial folds in need of structural correction.
  • Jawline contouring to create sharper, more defined mandibular angles.
  • Chin augmentation and projection for improved facial harmony and profile.
  • Cheek augmentation and sculpting for volume restoration and contour definition.
  • General facial augmentation in areas requiring high-viscosity filler and clear structural repair.
  • Deep to severe wrinkles in patients with significant age-related volume loss and contour changes.

Composition

  • Cross-linked hyaluronic acid 20 mg/mL (high-purity, non-animal sourced).
  • Cross-linking agent: BDDE (1,4-Butanediol diglycidyl ether) used at a minimised level, with advanced BDDE residual washing technology (exact residual level as per IFU).
  • Physiological, sterile, pyrogen-free buffer solution as carrier (exact excipients listed on product carton/leaflet).
  • Without lidocaine (formulation distributed by Cosmetix and other EU/UK wholesalers is supplied without local anaesthetic).

Formulation

  • High-viscosity, strongly cross-linked hyaluronic acid gel for deep structural support.
  • Monophasic tissue filler line from BR PHARM with Premium SubQ formulated as the thickest and most durable variant in the Revitrane range.
  • Dense, cohesive gel with very large particle size designed to create sharp, defined features and long-lasting volume.
  • High viscoelasticity for natural lifting effects combined with excellent cohesiveness to maintain shape and reduce migration.
  • Minimal BDDE cross-linking rate and low endotoxin levels for enhanced safety and reduced risk of adverse reactions.
  • Class III CE-marked injectable medical device intended for professional use in deep dermis, subcutaneous and supraperiosteal planes as per injector training and product IFU.

Packaging

  • Each unit box contains 1 x 1ml pre-filled sterile glass syringe of Revitrane Premium SubQ.
  • Supplied in a sterile blister tray within an outer printed carton.
  • Carton labelled with product name, volume, batch/lot number, expiry date, CE marking, manufacturer (BR PHARM Co., Ltd.) and basic usage information.
  • Distributors may supply appropriate needles or recommend compatible gauge cannulas (typically 25G or larger) depending on local practice, but Premium SubQ packs are commonly supplied with a pre-filled syringe only.
  • Single-use sterile device; any unused portion after a treatment session must be discarded.

Usage

  • For use only by appropriately trained and qualified healthcare professionals experienced in dermal filler injections and familiar with facial anatomy and complication management.
  • Obtain a complete medical history, including allergies, medications (especially anticoagulants/antiplatelets) and previous aesthetic treatments; perform a full facial assessment and discuss expectations and risks with the patient before obtaining informed consent.
  • Check the package integrity and expiry date; do not use if the sterile blister or syringe is damaged or if the product has expired or been improperly stored.
  • Cleanse and disinfect the treatment area thoroughly using an appropriate skin antiseptic, taking care to avoid contact with eyes and mucous membranes.
  • Attach a suitable sterile needle or cannula (commonly 25G or similar for deep structural work) firmly to the syringe; expel any air and a small droplet of gel before injection.
  • Inject slowly into the recommended tissue planes (deep dermis, subcutaneous or supraperiosteal, depending on indication and technique) using appropriate methods such as linear threading, fanning or depot injections, avoiding intravascular injection at all times.
  • Gradually build volume and frequently assess symmetry and contour; avoid overcorrection as the filler provides strong lift and projection.
  • After injection, gently mold and contour the area with light fingertip pressure to refine shape and integration, avoiding aggressive massage.
  • Provide written and verbal aftercare: avoid makeup on treated areas for several hours; avoid excessive heat or cold exposure, vigorous exercise, alcohol, and massage or pressure on the treated areas for 24–48 hours; protect skin from intense sun exposure.
  • Advise patients to contact the clinic immediately if they experience severe or disproportionate pain, blanching, colour change, visual disturbances, marked swelling, or other signs suggestive of vascular compromise or significant adverse events.
  • Dispose of used needles, cannulas and syringes in appropriate clinical sharps containers according to local regulations.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid or any excipient in the product.
  • History of severe anaphylactic reactions or multiple serious allergies.
  • Presence of active skin infection, inflammation or disease (e.g., acne, herpes simplex, dermatitis) at or near the intended injection site.
  • Previous injection of permanent or semi-permanent fillers in or near the planned treatment area, unless the practitioner is confident that combination is safe.
  • Patients with uncontrolled bleeding disorders or those on significant anticoagulant/antiplatelet therapy without appropriate risk-benefit assessment.
  • Pregnancy and breastfeeding, as safety has not been established; treatment is generally not recommended.
  • Patients with severe autoimmune disease or significant immunosuppression, unless treatment is undertaken with specialist input and careful risk assessment.
  • Intravascular injection is strictly contraindicated; do not inject into blood vessels or in a manner that risks intravascular placement.

Adverse Effects

  • Common, usually transient injection-site reactions: erythema (redness), swelling, tenderness, pain, bruising, itching and local warmth; these typically resolve within a few days to two weeks.
  • Temporary palpable nodules, lumps or surface irregularities that may resolve spontaneously, with gentle massage, or require clinical management.
  • Less common events: local infection, prolonged edema, delayed-onset nodules or granulomatous reactions, or inflammatory responses.
  • Vascular occlusion due to inadvertent intravascular injection or external compression, presenting with severe pain, blanching, colour change, livedo reticularis or tissue ischemia; if not promptly treated, this may lead to tissue necrosis and scarring and constitutes a medical emergency.
  • Very rare but serious complications associated with dermal fillers in high-risk areas (e.g., perinasal, periorbital): visual disturbances, blindness, stroke-like symptoms or other neurological deficits due to embolisation of filler material.
  • Immediate or delayed hypersensitivity reactions, including rare cases of anaphylaxis.
  • Any persistent, unusual or severe adverse event should prompt urgent clinical review and, where required, reporting to relevant regulatory authorities.

Storage Conditions

  • Store the product in its original packaging at a controlled room temperature as specified in the official product leaflet (typically between about 2°C and 25°C); do not freeze.
  • Keep away from direct sunlight, excessive heat and moisture.
  • Do not use if the syringe has been frozen, overheated or otherwise improperly stored, or if packaging is damaged or opened before intended use.
  • Keep out of reach of children and unauthorised individuals.
  • Single-use only; once opened and used for a patient, any remaining gel must be discarded safely.

Duration

Results with Revitrane Premium SubQ are generally described as long-lasting, with many distributors stating effects of up to approximately 10 months, depending on treatment area, injection technique, product volume, and individual patient factors such as metabolism, lifestyle and skin quality.

Onset

Immediate volumising and contouring effect at the time of injection, with final aesthetic outcome typically visible once any initial swelling and bruising subside over the first few days; tissue integration and hydration effects may further refine the result over subsequent weeks.

Browse more Medical aesthetics

Top Treatments

Top Cities in the UK